Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-12-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于调整2022年限制性股票激励计划授予价格的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the adjustment of the grant price for its 2022 restricted stock incentive plan. It details board and supervisory approvals, legal opinions, and the rationale for the price adjustment following the company's 2022 dividend distribution. The document does not contain financial statements or detailed financial performance data but rather focuses on corporate governance and incentive plan adjustments. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting result announcement. The content fits best as a regulatory announcement about management decisions related to stock incentive plans, which aligns with the category of Regulatory Filings (RNS). The document length is under 5,000 characters, and it is a formal announcement rather than a report itself, reinforcing the RNS classification.
2023-12-01 Chinese
国浩律师（深圳）事务所关于深圳华大基因股份有限公司2022年限制性股票激励计划之授予价格调整及预留部分授予事项的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the grant price and reserved portion of a 2022 restricted stock incentive plan for Shenzhen BGI Genomics Co., Ltd. It details the legal compliance, approval procedures, and specific adjustments related to the stock incentive plan. The document is a standalone legal opinion on a specific corporate action related to stock incentives, not a full annual or interim financial report, earnings release, or management discussion. It is not a regulatory announcement or a brief notice but a detailed legal opinion. This fits best under the category of Audit Report / Information (AR), as it involves legal and compliance verification related to corporate governance and stock incentive adjustments, which is typical for audit or legal opinion reports accompanying corporate filings. FY 2023
2023-12-01 Chinese
公司章程（2023年12月）
Governance Information Classification · 100% confidence The document is titled "深圳华大基因股份有限公司章程" which translates to "Articles of Association of BGI Genomics Co., Ltd." It contains detailed sections on company organization, shareholder rights, board of directors, management, financial accounting systems, profit distribution, auditing, and other governance-related topics. It references Chinese company law and securities law, and includes detailed provisions on shareholder meetings, share issuance, share transfer, board responsibilities, and internal controls. The document is a comprehensive set of corporate governance rules and internal regulations rather than a financial report or announcement. It is not an annual report, audit report, earnings release, or any other financial filing. It is a governance document outlining the company's internal rules and structure. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is the full governance document, not a brief announcement or summary.
2023-12-01 Chinese
董事会薪酬与考核委员会实施细则（2023年12月）
Governance Information Classification · 95% confidence The document is titled as the "Implementation Rules of the Board of Directors' Remuneration and Assessment Committee" of Shenzhen BGI Genomics Co., Ltd. It details the structure, responsibilities, and procedures of the Remuneration and Assessment Committee under the Board of Directors. The content focuses on governance aspects related to remuneration policies, assessment standards, committee composition, meeting rules, and decision-making processes. There is no financial data, earnings information, or report publication announcement. The document is a governance-related internal rules and procedures report, fitting the category of Governance Information (CGR). The document length is about 3,095 characters, which is consistent with a detailed governance policy document rather than a brief announcement or a full financial report.
2023-12-01 Chinese
董事会议事规则（2023年12月）
Governance Information Classification · 95% confidence The document is titled '董事会议事规则' which translates to 'Board Meeting Rules' or 'Rules of Procedure for the Board of Directors' of Shenzhen BGI Genomics Co., Ltd. The content details the procedures, responsibilities, meeting types, voting rules, and other governance-related protocols for the company's board meetings. It references relevant laws and company bylaws but does not contain financial data, audit results, or shareholder voting results. It is a governance document outlining internal board rules rather than a report, announcement, or financial filing. Therefore, it fits best under Governance Information (CGR). The document length (7054 characters) and detailed procedural content support this classification with high confidence.
2023-12-01 Chinese
2022年限制性股票激励计划预留授予激励对象名单（截至预留授予日）
Remuneration Information Classification · 95% confidence The document is a detailed announcement of the 2022 restricted stock incentive plan reserved grant list for Shenzhen BGI Genomics Co., Ltd. It includes specific allocations of restricted stock to management and core business personnel, with percentages relative to total equity and company share capital. The document also lists the names and positions of the incentive recipients. This content relates to stock-based compensation and incentive plans, which typically fall under remuneration or compensation disclosures. There is no indication that this is a full annual report, audit report, earnings release, or other financial report. It is not a proxy solicitation or voting result announcement. The document is not a brief announcement but contains substantive information about stock incentives. Therefore, the best fitting category is Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including stock incentive plans.
2023-12-01 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.